BioXcel Therapeutics Says TRANQUILITY II Phase 3 Trial Of BXCL501 For Acute Treatment Of Alzheimer's Disease-Related Agitation Met Its Primary Endpoint With The 60mcg Dose
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics announced that its TRANQUILITY II Phase 3 trial of BXCL501 for the acute treatment of Alzheimer's disease-related agitation has met its primary endpoint with the 60mcg dose.
June 29, 2023 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics' successful Phase 3 trial of BXCL501 could potentially lead to a new treatment for Alzheimer's disease-related agitation, which may positively impact the company's stock.
The successful completion of a Phase 3 trial is a significant milestone in drug development. This success could potentially lead to the approval and commercialization of BXCL501, which would likely increase BioXcel's revenues and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100